Efficacy and safety of tofacitinib modified-release 11 mg once daily plus methotrexate in adult patients with rheumatoid arthritis: 24-week open-label phase results from a phase 3b/4 methotrexate withdrawal non-inferiority study (ORAL Shift)

OBJECTIVES: To report the efficacy, safety and patient-reported outcome measures (PROs) of tofacitinib modified-release 11 mg once daily plus methotrexate in patients with rheumatoid arthritis (RA) from the open-label phase of Oral Rheumatoid Arthritis Trial (ORAL) Shift. METHODS: ORAL Shift was a g...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen, Stanley B, Pope, Janet, Haraoui, Boulos, Mysler, Eduardo, Diehl, Annette, Lukic, Tatjana, Liu, Shixue, Stockert, Lori, Germino, Rebecca, Menon, Sujatha, Shi, Harry, Keystone, Edward C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8190053/
https://www.ncbi.nlm.nih.gov/pubmed/34103405
http://dx.doi.org/10.1136/rmdopen-2021-001673

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8190053/
https://www.ncbi.nlm.nih.gov/pubmed/34103405
http://dx.doi.org/10.1136/rmdopen-2021-001673

Ejemplares similares